Linda Schäker-Hübner

8PUBLICATIONS
20CO-AUTHORS
Molecular targetsCheminformatics and quantitative structure-activity relationshipsCharacterisation of biological macromoleculesCancer therapy (excl. chemotherapy and radiation therapy)Medical devices
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 17, 2026
Novel Class I HDAC Inhibitors Sensitize Ovarian Cancer Cells for Cisplatin and Niraparib via an HDAC3-SLFN11 Axis.

|Apr 14, 2026
Cellular Target Engagement and Dissociation Kinetics of Class I-Selective Histone Deacetylase (HDAC) Inhibitors.

Irina Honin, Zora Novakova, Felix Feller

|Mar 19, 2026
Recommended Tool Compounds: Isoform- and Class-Specific Histone Deacetylase Inhibitors.

Linda Schäker-Hübner, Finn K Hansen

|Dec 18, 2025
Ortho-Hydroxyanilides: Slow-Acting, Selective Histone Deacetylase 1/2 Inhibitors Suitable for Photocaging Applications.

Irina Honin, Tao Sun, Nisha Setia

|Oct 16, 2024
Triple Combination of Entinostat, a Bromodomain Inhibitor, and Cisplatin Is a Promising Treatment Option for Bladder Cancer.

Lukas M Bollmann, Friedrich Lange, Alexandra Hamacher

|Mar 29, 2023
Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy.

Fabian B Kraft, Maria Hanl, Felix Feller

Pageof 2

Frequent Collaborators

8 joint publications

Finn K Hansen

2 joint publications

Gerd Bendas

1 joint publications

Oliver Clauß

1 joint publications

Barbara Wenzel